强化阿托伐他汀治疗对ACS合并糖尿病患者炎性因子及血脂的影响

Effect of intensive atorvastatin therapy on inflammatory factor and lipid levels of acute coronary syndrome with diabetes

目的研究不同剂量阿托伐他汀治疗对急性冠脉综合征(ACS)合并糖尿病患者炎症因子及血脂的影响。方法入选82例合并糖尿病的ACS患者,分为常规治疗组46例和强化治疗组36例;常规治疗组给予阿托伐他汀20 mg/d;强化治疗组给予阿托伐他汀40 mg/d,于治疗前、治疗后4周空腹采血,对两组患者血清高敏C-反应蛋白(hs CRP)、同型半胱氨酸(Hcy)及血脂进行分析。结果 4周后,两组患者血清hs CRP、Hcy及血清低密度脂蛋白(LDL-C)浓度均较治疗前明显下降(P<0.05)。与常规治疗组相比,强化治疗组血清hs CRP、Hcy及LDL-C浓度下降更加明显(P<0.05)。结论强化他汀类药物治疗能更好地降低ACS合并糖尿病患者炎症因子及血脂水平。

Objective To investigate the effect of different doses atorvastatin therapy on inflammatory factor and blood lipid levels of patients with acute coronary syndrome （ACS） and diabetes. Methods Eighty-two eases of ACS patients with diabetes were randomly divided into regular and intensive groups. Patients in regular group （n=46） were re6eived ator- vastatin 20 mg/d and in intensive group （n=36） atorvastatin 40 mg/d. The fasting blood serum high-sensitivity C-reac- tive protein （hsCRP）, homocysteine （Hcy） and lipid levels were analyzed before and 4 weeks after treatment. Results The serum hsCRP, Hey and LDL-C were significantly decreased than that before treatment（P〈O.05）. Compared with the regular group, the serum hsCRP, Hcy and LDL-C were lower in intensive group（P〈0.05）. Conclusion The intensive a- torvastatin therapy is better in reducing inflammatory factor and blood lipids for ACS patients with diabetes.